Endotoxin-binding affinity of sevelamer: A potential novel anti-inflammatory mechanism

Kidney International

Volumn 76, Issue SUPPL. 114, 2009, Pages

  Sun, Phyllis P ^a   Perianayagam, Mary C ^a   Jaber, Bertrand L ^a  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

Bacterial translocation; Inflammation; Lipopolysaccharide; Sevelamer

Indexed keywords

BILE ACID; ENDOTOXIN; LIPOPOLYSACCHARIDE; SEVELAMER; ANTIINFLAMMATORY AGENT; CHELATING AGENT; POLYAMINE;

ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; CHRONIC KIDNEY DISEASE; HUMAN; INTESTINE; PRIORITY JOURNAL; REVIEW; CHRONIC KIDNEY FAILURE; INFLAMMATION; METABOLISM;

ANTI-INFLAMMATORY AGENTS; BILE ACIDS AND SALTS; CHELATING AGENTS; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; LIPOPOLYSACCHARIDES; POLYAMINES;

EID: 77449086886     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.403     Document Type: Review

References (63)

1. Reitschel ET, Kirikae T, Schade FU et al. The chemical structure of bacterial endotoxin in realtion to bioactivity. Immunobiology 1993; 187: 169-190. (Pubitemid 23150766)
2. Bosshart H, Heinzelmann M. Targeting bacterial endotoxin: two sides of a coin. Ann N Y Acad Sci 2007; 1096: 1-17. (Pubitemid 47092492)
3. Herselman M, Moosa MR, Kotze TJ et al. Protein-energy malnutrition as a risk factor for increased morbidity in long-term hemodialysis patients. J Ren Nutr 2000; 10: 7-15.
4. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002; 15: 329-337. (Pubitemid 35007560)
5. Wanner C, Zimmermann J, Schwedler S et al. Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl 2002; 80: S99-S102. (Pubitemid 34534168)
6. Genth-Zotz S, von Haehling S, Bolger AP et al. Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. Am J Cardiol 2002; 90: 1226-1230. (Pubitemid 35346880)
7. Gonclaves S, Pecoits-Filho R, Perreto S. Fluid overload is associated with endotoxinemia but not with systemic inflammation in chronic kidney disease patients. J Am Soc Nephrol 2005; 16: 470A.
8. Holzheimer RG. The significance of endotoxin release in experimental and clinical sepsis in surgical patients - evidence for antibiotic-induced endotoxin release? Infection 1998; 26: 77-84.
9. Mock CN, Jurkovich GJ, Dries DJ et al. Clinical significance of antibiotic endotoxin-releasing properties in trauma patients. Arch Surg 1995; 130: 1234-1240; discussion 1240-1241.
10. Arizono K, Nomura K, Motoyama T et al. Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis. Blood Purif 2004; 22(Suppl 2): 26-29.
11. Hsu PY, Lin CL, Yu CC et al. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study. J Nephrol 2004; 17: 693-700.
12. Van Leeuwen PA, Boermeester MA, Houdijk AP et al. Clinical significance of translocation. Gut 1994, 35(Suppl 1): S28-S34.
13. Jacob AI, Goldberg PK, Bloom N et al. Endotoxin and bacteria in portal blood. Gastroenterology 1977; 72: 1268-1270.
14. Mathison JC, Ulevitch RJ. The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. J Immunol 1979; 123: 2133-2143.
15. Ruiter DJ, van der Meulen J, Brouwer A et al. Uptake by liver cells of endotoxin following its intravenous injection. Lab Invest 1981; 45: 38-45. (Pubitemid 11059989)
16. Kotanko P, Carter M, Levin NW. Intestinal bacterial microflora -a potential source of chronic inflammation in patients with chronic kidney disease. Nephrol Dial Transplant 2006; 21: 2057-2060. (Pubitemid 44295025)
17. Nolan JP, Hare DK, McDevitt JJ et al. In vitro studies of intestinal endotoxin absorption. I. Kinetics of absorption in the isolated everted gut sac. Gastroenterology 1977; 72: 434-439.
18. Hollander D, Vadheim CM, Brettholz E et al. Increased intestinal permeability in patients with Crohn's disease and their relatives. Am Intern Med 1986; 105: 883-885. (Pubitemid 19239031)
19. Rattan R, Giri S, Singh AK et al. Rho A negatively regulates cytokinemediated inducible nitric oxide synthase expression in brain-derived transformed cell lines: negative regulation of IKKa. Free Radic Biol Med 2003; 35: 1037-1050. (Pubitemid 37315697)
20. Openshaw PJ. Crossing barriers: infections of the lung and the gut. Mucosal Immunol 2009; 2: 100-102.
21. Nakagawa K, Matsubara S, Ouchi K et al. Endotoxemia after abdominal surgery. Tohoku J Exp Med 1986; 150: 273-280.
22. Seal M, Naito Y, Barreto R et al. Experimental radiotherapy-induced enteritis: a probiotic interventional study. J Dig Dis 2007; 8: 143-147. (Pubitemid 47161787)
23. Do Carmo S, Levros Jr LC, Rassart E. Modulation of apolipoprotein D expression and translocation under specific stress conditions. Biochim Biophys Acta 2007; 1773: 954-969. (Pubitemid 46839140)
24. Rothman D, Latham MC, Walker WA. Transport of macromolecules in malnourished animals. Nutr Res 1982; 2: 467-472.
25. Li M, Specian RD, Berg RD et al. Effects of protein malnutrition and endotoxin on the intestinal mucosal barrier to the translocation of indigenous flora in mice. JPEN J Parenter Enteral Nutr 1989; 13: 572-578. (Pubitemid 20005552)
26. Saito H, Trocki O, Alexander JW et al. The effect of route of nutrient administration on the nutritional state, catabolic hormone secretion, and gut mucosal integrity after burn injury. JPEN J Parenter Enteral Nutr 1987; 11: 1-7. (Pubitemid 17009507)
27. Alverdy J, Chi HS, Sheldon GF. The effect of parenteral nutrition on gastrointestinal immunity. The importance of enteral stimulation. Ann Surg 1985; 202: 681-684.
28. Kolios G, Valatas V, Manousou P et al. Nitric oxide and MCP-1 regulation in LPS activated rat Kupffer cells. Mol Cell Biochem 2008; 319: 91-98.
29. Charalambous BM, Stephens RC, Feavers IM et al. Role of bacterial endotoxin in chronic heart failure: the gut of the matter. Shock 2007; 28: 15-23. (Pubitemid 46956457)
30. Magnusson M, Magnusson KE, Sundqvist T et al. Increased intestinal permeability to differently sized polyethylene glycols in uremic rats: effects of low- and high-protein diets. Nephron 1990; 56: 306-311. (Pubitemid 20330099)
31. Magnusson M, Magnusson KE, Sundqvist T et al. Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure. Gut 1991; 32: 754-759.
32. Kang JY. The gastrointestinal tract in uremia. Dig Dis Sci 1993; 38: 257-268.
33. Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis 2007; 14: 82-99. (Pubitemid 46014531)
34. Bratten JR, Jones MP. Small intestinal motility. Curr Opin Gastroenterol 2007; 23: 127-133.
35. Simenhoff ML, Dunn SR, Zollner GP et al. Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried Lactobacillus acidophilus. Miner Electrolyte Metab 1996; 22: 92-96.
36. Hida M, Aiba Y, Sawamura S et al. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 1996; 74: 349-355. (Pubitemid 26326708)
37. Douglas LC, Sanders ME. Probiotics and prebiotics in dietetics practice. J Am Diet Assoc 2008; 108: 510-521.
38. Andrä J, Gutsmann T, Garidel P et al. Mechanisms of endotoxin neutralization by synthetic cationic compounds. J Endotoxin Res 2006; 12: 261-277. (Pubitemid 47471338)
39. Jaber BL, Pereira BJ. Extracorporeal adsorbent-based strategies in sepsis. Am J Kidney Dis 1997; 30(Suppl 4): S44-S56.
40. Duggal A, Hanus M, Zhorov E et al. Novel dosage forms and regimens for sevelamer-based phosphate binders. J Ren Nutr 2006; 16: 248-252. (Pubitemid 43975000)
41. Plone MA, Petersen JS, Rosenbaum DP et al. Sevelamer, a phosphatebinding polymer, is a non-absorbed compound. Clin Pharmacokinet 2002; 41: 517-523.
42. Burke SK. Renagel: reducing serum phosphorus in haemodialysis patients. Hosp Med 2000; 61: 622-627.
43. Chertow GM, Burke SK, Lazarus JM et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997; 29: 66-71.
44. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252. (Pubitemid 34754068)
45. De Smet R, Thermote F, Lamiere N. Sevelamer hydrochloride adsorbs the uremic compound indoxyl sulfate. J Am Soc Nephrol 2003; 14: 206A.
46. Garg JP, Chasan-Taber S, Blair A et al. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum 2005; 52: 290-295. (Pubitemid 40129261)
47. De Santo NG, Frangiosa A, Anastasio P et al. Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol 2006; 19(Suppl 9): S108-S114. (Pubitemid 44420095)
48. John-Kalarickal J, Pearlman G, Carlson HE. New medications which decrease levothyroxine absorption. Thyroid 2007; 17: 763-765. (Pubitemid 350194737)
49. Kays MB, Overholser BR, Mueller BA et al. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am J Kidney Dis 2003; 42: 1253-1259. (Pubitemid 37486770)
50. Cizman B. Hyperphosphataemia and treatment with sevelamer in haemodialysis patients. Nephrol Dial Transplant 2003; 18(Suppl 5): v47-v49. (Pubitemid 36896452)
51. Shantouf R, Budoff MJ, Ahmadi N et al. Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients. Am J Nephrol 2008; 28: 275-279.
52. Phan O, Ivanovski O, Nguyen-Khoa T et al. Sevelamer prevents uremiaenhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 2005; 112: 2875-2882. (Pubitemid 41641683)
53. Salusky IB. A new era in phosphate binder therapy: what are the options? Kidney Int Suppl 2006; 105: S10-S15.
54. Rao M, Jaber BL, Balakrishnan VS. Inflammatory biomarkers and cardiovascular risk: association or cause and effect? Semin Dial 2006; 19: 129-135.
55. Ferramosca E, Burke S, Chasan-Taber S et al. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005; 149: 820-825. (Pubitemid 40718876)
56. Yamada K, Fujimoto S, Tokura T et al. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients. Ren Fail 2005; 27: 361-365. (Pubitemid 40993682)
57. Perianayagam MC, Jaber BL. Endotoxin-binding affinity of sevelamer hydrochloride. Am J Nephrol 2008; 28: 802-807.
58. Sun PP, Perianayagam MC, Jaber BL. Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study. J Ren Nutr 2009; 19: 432-438.
59. Harris HW, Grunfeld C, Feingold KR et al. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest 1990; 86: 696-702. (Pubitemid 20327356)
60. Harris HW, Grunfeld C, Feingold KR et al. Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. J Clin Invest 1993; 91: 1028-1034. (Pubitemid 23095278)
61. Read TE, Harris HW, Grunfeld C et al. Chylomicrons enhance endotoxin excretion in bile. Infect Immun 1993; 61: 3496-3502. (Pubitemid 23223444)
62. Harris HW, Brady SE, Rapp JH. Hepatic endosomal trafficking of lipoprotein-bound endotoxin in rats. J Surg Res 2002; 106: 188-195. (Pubitemid 35041717)
63. Braunlin W, Zhorov E, Guo A et al. Bile acid binding to sevelamer HCl. Kidney Int 2002; 62: 611-619. (Pubitemid 34779775)